Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 10, Issue 6, Pages 967-981Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560902834961
Keywords
breast cancer; chemotherapy; endocrine therapy; metastatic disease; targeted agents
Categories
Ask authors/readers for more resources
Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available